These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 26058997)

  • 1. [The subcutaneous cardioverter-defibrillator: When less is more].
    Kuschyk J; Rudic B; Akin I; Borggrefe M; Röger S
    Herzschrittmacherther Elektrophysiol; 2015 Jun; 26(2):123-8. PubMed ID: 26058997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies.
    Brouwer TF; Knops RE; Kutyifa V; Barr C; Mondésert B; Boersma LVA; Lambiase PD; Wold N; Jones PW; Healey JS
    Europace; 2018 Sep; 20(FI2):f240-f248. PubMed ID: 29771327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sudden cardiac death: New approaches for implantable cardioverter-defibrillators (ICDs).
    Cappato R; Ali H
    Int J Cardiol; 2017 Jun; 237():38-41. PubMed ID: 28377192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of the subcutaneous implantable cardioverter-defibrillator for reducing sudden cardiac death.
    Sanghera R; Sanders R; Husby M; Bentsen JG
    Ann N Y Acad Sci; 2014 Nov; 1329():1-17. PubMed ID: 25308791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The subcutaneous implantable cardioverter-defibrillator in review.
    Kamp NJ; Al-Khatib SM
    Am Heart J; 2019 Nov; 217():131-139. PubMed ID: 31654943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
    Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and early clinical outcomes of patients undergoing totally subcutaneous vs. transvenous single chamber implantable cardioverter defibrillator placement.
    Mithani AA; Kath H; Hunter K; Andriulli J; Ortman M; Field J; Russo AM
    Europace; 2018 Feb; 20(2):308-314. PubMed ID: 28383717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy.
    Brouwer TF; Yilmaz D; Lindeboom R; Buiten MS; Olde Nordkamp LR; Schalij MJ; Wilde AA; van Erven L; Knops RE
    J Am Coll Cardiol; 2016 Nov; 68(19):2047-2055. PubMed ID: 27810043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shock Without Wires: A Look at Subcutaneous Implantable Cardioverter-Defibrillator Compared to Transvenous Implantable Cardioverter-Defibrillator for Ventricular Arrhythmias.
    Raja J; Guice K; Oberoi M; Whitwell S; Asbeutah AA; Russell A; Khouzam RN
    Curr Probl Cardiol; 2022 Sep; 47(9):100927. PubMed ID: 34311985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimally invasive epicardial implantable cardioverter-defibrillator placement for infants and children: An effective alternative to the transvenous approach.
    Schneider AE; Burkhart HM; Ackerman MJ; Dearani JA; Wackel P; Cannon BC
    Heart Rhythm; 2016 Sep; 13(9):1905-12. PubMed ID: 27321244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The need for a subsequent transvenous system in patients implanted with subcutaneous implantable cardioverter-defibrillator.
    Gasperetti A; Schiavone M; Vogler J; Laredo M; Fastenrath F; Palmisano P; Ziacchi M; Angeletti A; Mitacchione G; Kaiser L; Compagnucci P; Breitenstein A; Arosio R; Vitali F; De Bonis S; Picarelli F; Casella M; Santini L; Pignalberi C; Lavalle C; Pisanò E; Ricciardi D; Calò L; Curnis A; Bertini M; Gulletta S; Dello Russo A; Badenco N; Tondo C; Kuschyk J; Tilz R; Forleo GB; Biffi M
    Heart Rhythm; 2022 Dec; 19(12):1958-1964. PubMed ID: 35781042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing the use of subcutaneous or transvenous implantable cardioverter-defibrillators: results of the European Heart Rhythm Association prospective survey.
    Boveda S; Lenarczyk R; Fumagalli S; Tilz R; Goscinska-Bis K; Kempa M; Defaye P; Marquié C; Capucci A; Ueberham L; Dagres N
    Europace; 2018 May; 20(5):887-892. PubMed ID: 29432525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous implantable cardioverter-defibrillator (S-ICD).
    Lobodzinski SS
    Cardiol J; 2011; 18(3):326-31. PubMed ID: 21660928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ICD leads].
    Israel CW; Sheta MK
    Herzschrittmacherther Elektrophysiol; 2015 Jun; 26(2):94-104. PubMed ID: 26036679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator.
    Honarbakhsh S; Providencia R; Srinivasan N; Ahsan S; Lowe M; Rowland E; Hunter RJ; Finlay M; Segal O; Earley MJ; Chow A; Schilling RJ; Lambiase PD
    Int J Cardiol; 2017 Feb; 228():280-285. PubMed ID: 27865198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy.
    Olde Nordkamp LR; Knops RE; Bardy GH; Blaauw Y; Boersma LV; Bos JS; Delnoy PP; van Dessel PF; Driessen AH; de Groot JR; Herrman JP; Jordaens LJ; Kooiman KM; Maass AH; Meine M; Mizusawa Y; Molhoek SG; van Opstal J; Tijssen JG; Wilde AA
    Am Heart J; 2012 May; 163(5):753-760.e2. PubMed ID: 22607851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies.
    Basu-Ray I; Liu J; Jia X; Gold M; Ellenbogen K; DiNicolantonio J; Komócsi A; Vorobcsuk A; Kim J; Afshar H; Lam W; Mathuria N; Razavi M; Rasekh A; Saeed M
    JACC Clin Electrophysiol; 2017 Dec; 3(13):1475-1483. PubMed ID: 29759827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-traditional implantable cardioverter-defibrillator configurations and insertion techniques: a review of contemporary options.
    Tonko JB; Rinaldi CA
    Europace; 2022 Feb; 24(2):181-192. PubMed ID: 34453529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.